Chinese Rheumatism Biobank(CRB)

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

April 1, 2033

Conditions
Lupus Erythematosus, Systemic
Interventions
DRUG

Antimalarial with or without oral glucocorticosteroid

"Intervention one: Antimalarial and Oral Glucocorticosteroid, Prednisone or equivalent dose of glucocorticoid tapering: 0.5\~0.6mg/kg/d(week 0\~2), 0.3\~0.4mg/kg/d(week 3\~4), 15 mg/d(week 5\~6), 10 mg/d(week 7\~8), 7.5 mg /d(week 9\~10), 5 mg/d(week 11\~12), 2.5 mg/d(week 13\~24), \<2.5 mg/d(after week 24);Hydroxychloroquin 6.5mg/kg/d but no more than 400mg/d for initial therapy, and reduce to 4\~5mg/kg/d for maintenance therapy~Intervention two: Antimalarial only. Hydroxychloroquin 6.5mg/kg/d but no more than 400mg/d for initial therapy, and reduce to 4\~5mg/kg/d for maintenance therapy"

Trial Locations (1)

100730

RECRUITING

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing

All Listed Sponsors
lead

Chinese SLE Treatment And Research Group

OTHER